FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints

As FDA started to reconsider the approval of Roche/Genentech's Avastin for metastatic breast cancer, many were concerned about the decision's potential implications for other applications using progression-free survival as an endpoint.